Genetown
Filter News
Found 58,863 articles
-
Janice Kranz, the company’s co-founder and chief executive officer took time to speak with BioSpace about the company and its approach to Alzheimer’s disease and other tauopathies.
-
Cheetah Medical Presents Correlation Between Starling™ SV Use and Sepsis Management at the CHEST Annual Meeting 2019 International Conference
10/23/2019
Cheetah Medical, a medical device leader in non-invasive fluid management technology, today delivered a presentation at the American College of Chest Physicians’ Annual Meeting in New Orleans, Louisiana, showing that hospitals with the highest use of Cheetah Medical’s Starling SV™ exhibited the greatest levels of compliance with The Center for Medicare and Medicaid Services sepsis (SEP-1) measures.
-
Pega Achieves HITRUST CSF® Certification to Manage Risk, Improve Security Posture, and Meet Compliance Requirements
10/23/2019
Pegasystems Inc. (NASDAQ: PEGA), the software company empowering digital transformation at the world's leading enterprises, today announced Pega Cloud® has earned certified status for information security by HITRUST.
-
Selecta Biosciences Presents New Preclinical Data from its Gene Therapy Program at 2019 ESGCT Annual Congress
10/23/2019
Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today presented new preclinical data from its gene therapy program at the European Society of Gene and Cell Therapy (ESGCT) Annual Congress from October 22-25, 2019 in Barcelona, Spain.
-
Axcella Enters into Collaboration with CYTOO to Explore Impact of Dysregulated Metabolism on Muscle Physiology
10/23/2019
Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today announced a collaboration with CYTOO aimed at informing the development of new AXA Candidates by leveraging CYTOO’s MyoScreenTM muscle-on-a-plate platform.
-
Alnylam to Webcast Conference Call Discussing Third Quarter 2019 Financial Results
10/23/2019
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2019 on Thursday, October 31, 2019,
-
Cedilla Therapeutics Appoints Justin Birtz as Vice President, People and Culture
10/23/2019
Cedilla Therapeutics, a preclinical biotech company harnessing protein stability to create the next generation of targeted cancer therapies, today announced the appointment of Justin Birtz as vice president, people and culture.
-
Repligen to Report Third Quarter 2019 Financial ResultsWebcast and Conference Call to Be Held Thursday, October 31, 2019 at 8:30 a.m. EDT
10/23/2019
The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and nine-month reporting periods ended September 30, 2019.
-
ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
10/23/2019
Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases
-
Akcea Announces Appointment of New Chief Commercial OfficerKyle Jenne promoted from previous role as U.S. commercial lead to support continued strategic expansion of global commercial operations
10/23/2019
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that the company has promoted Kyle Jenne to chief commercial officer.
-
Collegium to Host Conference Call to Discuss Third Quarter 2019 Financial Results and Provide Corporate Update
10/23/2019
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Wednesday, November 6, 2019 at 4:30 p.m. Eastern Time.
-
Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of Directors
10/23/2019
Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced David Adair, M.D. will join the Mayfield Pharmaceuticals Board of Directors
-
The decision was based on new analysis run by Biogen in consultation with the FDA of a larger dataset from the trials halted in March.
-
The U.S. Food and Drug Administration approved a new cystic fibrosis medication that is expected to provide treatment for 90% of patients with this debilitating and life-shortening condition.
-
VBI Vaccines Announces Late-Breaker Poster Presentation at The Liver Meeting® 2019
10/22/2019
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that the company’s abstract titled, “Rapid Increase in Anti-HBsAg Titers and Higher Seroprotection Rates in Adults Immunized with Sci-B-Vac Compared to a Monovalent Hepatitis B Vaccine: Results from PROTECT – a Double-Blind, Randomized, Controlled, Phase-3 Study,
-
Compass Therapeutics Appoints Leading Immuno-Oncology Researchers to Its Immuno-Oncology Scientific Advisory Board
10/22/2019
Compass Therapeutics, a biotechnology company focused on drugging the human immune synapse to treat human diseases, today announced the appointment of a scientific advisory board made up of renowned immuno-oncology researchers with deep expertise in target biology, drug development and clinical trial design.
-
Cerevel Therapeutics Initiates Phase 1b Clinical Trial of CVL-231, a M4 Selective Positive Allosteric Modulator in Development for the Treatment of Schizophrenia
10/22/2019
Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today it has dosed the first patient in a Phase 1b clinical trial evaluating CVL-231 in patients with schizophrenia.
-
InVivo Therapeutics Provides Enrollment Update for INSPIRE 2.0 Study for the Treatment of Acute Spinal Cord Injury
10/22/2019
InVivo Therapeutics Holdings Corp. (NVIV) today announced that a total of five patients have been enrolled into The INSPIRE 2.0 Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury), bringing the study to 25% completion of targeted enrollment
-
Disarm Therapeutics Reports Preclinical Data Demonstrating Small Molecule SARM1 Inhibitors Preserve Both Axonal Structure and Function In Vitro and In Vivo
10/22/2019
Disarm Therapeutics, a biotechnology company creating a new class of disease-modifying therapeutics for patients with axonal degeneration, today announced preclinical data demonstrating that small molecule inhibitors of SARM1 protect axons in both in vitro and in vivo models of axonal degeneration.
-
Orchard Therapeutics Presents Data from OTL-200 in Patients with Metachromatic Leukodystrophy Using Cryopreservation
10/22/2019
Stable Levels of Engraftment and Reconstitution of Enzyme Activity in Patients with Up to 12 Months of Follow-up Indicate Similar Profiles Between Cryopreserved and Fresh Formulations